Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

COX-2 in inflammation and resolution.

Ravindra Rajakariar1, Muhammad M Yaqoob, Derek W Gilroy

  • 1Department of Experimental Medicine, Nephrology and Critical Care, William Harvey Research Institute, Charterhouse Square, London EC1M6BQ.

Molecular Interventions
|September 9, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: IkB Kinase Inhibitor Attenuates Sepsis-Induced Cardiac Dysfunction in CKD.

Journal of the American Society of Nephrology : JASN·2026
Same author

Divergent roles of skeletal muscle 11β-HSD1 in age-related and chronic kidney disease-associated sarcopenia.

European journal of endocrinology·2026
Same author

L-Glutamine attenuates peritoneal fibrosis developed in 5-Fluorouracil-treated mice.

Experimental biology and medicine (Maywood, N.J.)·2026
Same author

Retraction Note: Delayed administration of pyroglutamate helix B surface peptide (pHBSP), a novel nonerythropoietic analog of erythropoietin, attenuates acute kidney injury.

Molecular medicine (Cambridge, Mass.)·2026
Same author

POLB 001, a p38 MAPK inhibitor, decreases local and systemic inflammatory responses following <i>in vivo</i> LPS administration in healthy volunteers: a randomised, double-blind, placebo-controlled study.

Frontiers in immunology·2026
Same author

Challenges of monocyte HLA-DR targeted immunomodulation in sepsis-a prospective observational cohort study.

Frontiers in immunology·2026
Same journal

Spindle poisons and cell fate: a tale of two pathways.

Molecular interventions·2011
Same journal

CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle.

Molecular interventions·2011
Same journal

Finding homes for orphan cytochrome P450s: CYP4V2 and CYP4F22 in disease states.

Molecular interventions·2011
Same journal

New therapeutic approaches to combat arterial thrombosis: better drugs for old targets, novel targets, and future prospects.

Molecular interventions·2011
Same journal

The secrets of a successful clinical trial: compliance, compliance, and compliance.

Molecular interventions·2011
Same journal

Asthma therapeutics: recent strides, new hurdles.

Molecular interventions·2011
See all related articles

Aspirin reveals beneficial lipid mediators like epilipoxins, challenging the view that all inflammation-related eicosanoids are harmful. These compounds offer new avenues for disease control and drug discovery.

Area of Science:

  • Biochemistry
  • Immunology
  • Pharmacology

Background:

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin are widely used, often based on the premise that inhibiting prostaglandins reduces inflammation.
  • This view overlooks the complex roles of eicosanoids, a class of signaling molecules, in inflammatory processes.

Purpose of the Study:

  • To re-evaluate the role of eicosanoids in inflammation, moving beyond the simple inhibition of prostaglandins.
  • To highlight the significance of specific lipid mediators, such as epilipoxins, in regulating inflammation and its resolution.

Main Methods:

  • Investigated the biochemical pathways involving aspirin's interaction with cyclooxygenase-2 (COX-2).
  • Analyzed the production and function of aspirin-triggered epilipoxins (ATL) and other lipid mediators.

Related Experiment Videos

Main Results:

  • Demonstrated that aspirin's action on COX-2 generates epilipoxins, which possess anti-inflammatory properties.
  • Identified epilipoxins, resolvins, and specific COX-2-derived prostaglandins (D2, J2 series) as key immunoregulatory lipid mediators.

Conclusions:

  • The study challenges the traditional view of NSAIDs by revealing beneficial roles of certain eicosanoids.
  • Epilipoxins and related lipid mediators represent a promising area for developing novel therapeutic strategies for inflammatory diseases.